Other languages Arcutis Biotherapeutics, Inc.

Equities

ARQT

US03969K1088

Real-time Estimate Cboe BZX Other stock markets 03:27:48 2024-06-07 pm EDT			5-day change	1st Jan Change
7.315 ^USD	-3.75%		-13.04%	+125.08%

May. 28	Johnson & Johnson Acquires Experimental Eczema Drug for $1.25 Billion	MT
May. 15	Needham Adjusts Price Target on Arcutis Biotherapeutics to $18 From $16, Maintains Buy Rating	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Rise Pre-Bell Wednesday	May. 15
Sector Update: Health Care	May. 15
Arcutis Biotherapeutics Q1 Loss Narrows as Revenue Surges; Shares Soar Premarket	May. 15
Arcutis Biotherapeutics Q1 Loss Narrows, Revenue Increases; Shares Jump	May. 14
Arcutis Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 14
Arcutis Biotherapeutics, Inc. Announces Journal of Clinical and Aesthetic Dermatology Publishes the Outcomes of a Comprehensive Evaluation by an Expert Dermatology	May. 13
Arcutis Promotes Todd Tucker to Chief Human Resources Officer	Mar. 11
Arcutis Presents Late-Breaking Data from INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 At the American Academy of Dermatology Annual Meeting	Mar. 10
Arcutis Biotherapeutics Raises $172.5 Million in Common Stock Offering	Mar. 04
Arcutis Plans $150 Million Offering, Signs Collaboration, Licensing Deal for Roflumilast in Japan; Shares Fall After Hours	Feb. 28
Arcutis Biotherapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 27
Arcutis Biotherapeutics, Inc. Announces Publication of Positive Results from the Pivotal Phase 3 Trial Evaluating ZORYVE (roflumilast) Foam	Jan. 29
Arcutis Biotherapeutics Launches ZORYVE Topical Foam to Treat Seborrheic Dermatitis	Jan. 22
Arcutis Biotherapeutics, Inc. Announces New Subgroup Analysis Highlighting That Adults and Adopts ZoryVE Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical Steroids	Jan. 14
Arcutis Biotherapeutics, Inc. Announces New Individual Patient Response Data Showed at the 2024 Winter Clinical Dermatology Conference - Hawaii	Jan. 14
Sector Update: Health Care Stocks Mixed Pre-Bell Monday	Dec. 18
Sector Update: Health Care	Dec. 18
Top Premarket Gainers	Dec. 18
Arcutis Biotherapeutics Gets FDA Approval for Seborrheic Dermatitis Treatment -- Shares Surge Premarket	Dec. 18
MORNING BRIEFING - USA/Asien	Dec. 18

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Arcutis Biotherapeutics, Inc.

Equities

ARQT

US03969K1088

Other languages

Filters